I read an article about an MS patient wanting to do CCSVI.  I responded and liked the flow.  Here is a sample of my writing.

CCSVI is not a cure, but to my experience it is the best treatment for Multiple Sclerosis to date.
CCSVI is not a pill, so the tests needed are more complicated than the basic double blind testing for oral or iv drugs.
Canada has one of the highest concentrations of MS on the planet.  MS can be a serious drain on the government.  CCSVI offers a minimally invasive alternative that show greater promise.
The reality is that MS is an individual condition.  Two people may have MS, but their conditions will differ greatly.  CCSVI treatments have the same reality.
Our bodies are not cars.  We do not go in for service and come out better.
CCSVI works out to a 33% no improvment, 33% moderate, 33% major. 
I would think that standard medical testing wants the "car" test.  Go in, have procedure, get better.  MS does not allow CCSVI that simple of an outcome from testing.
Hence, testing may prove to be inconclusive to Medical professionals, Insurance companies and Governments.  Will they take a 66% success rate?

I know governments, and I am concerned.  The only project they would take a 66% success rate would be a program they designed, not a new procedure developed in Europe.  Plus, it takes a bed in a hospital.  And multiple people in the operating room.  For each of us.  Not a simple and low cost situation.

But a pill? The patient and pill.  Helps or does not.  Kills you or not.  Simple.

Everyone has a heart.  Hence I feel angioplasty was easy to fast track to approval globally.  CCSVI uses angioplasty in a new way.  Great, but angioplasty for the heart is compare test results and outcomes.  CCSVI is far more difficult because a follow up protocol has not even been established.  Most patients are happy to find a doctor, get the procedure scheduled, have CCSVI done and see what happens to the patient.

I want everyone to get better, but human nature makes us focus inward to a cure for the individual.